|
References Abraham, RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15: 2117-2196. Adshead JM, Kessling AM, Ogden CW. Genetic initiation, progression and prognostic markers in transitional cell carcinoma of the bladder: a summary of the structural and transcriptional changes, and the role of developmental genes. Br J Urol 1998; 82: 503-512. Alpan RS, Pardee AB. p21WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine. Cell Growth Differ. 1996; 7: 893-901. Bates S, Phillips AC, Clark PA Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumor suppressors RB and p53. Nature 1998; 395:124-125. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G., Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003; 63: 5224-5229. Berman J, Chesney MA. Complementary and alternative medicine in 2006: optimizing the dose of the intervention. Med J Aust 2005; 183 (11/12):574-575. Bernardini S, Fauconnet S, Chabannes E, et al. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166: 1275–1279. Bochner BH, Cote RJ, Weidner N Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer. relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995; 87: 1603–1612. Borden LS Jr, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2005;17: 275—280. Bringuier PP, Tamimi J, Schuurring E, Schalken J. Expression of cyclinD1 and EMS1 in bladder tumors: relationship with chromosome 11q13 amplification. Oncogene 1996; 14:1747-1753. Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM, Schalken JA. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumours. Cancer Res 1993; 53: 3241–3245. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary-bladder carcinoma (T24) containing tumor-specific antigen. Int. J. Cancer 1973; 11: 765-773. Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term follow-up. J Urol 2001; 165: 1473–1479. Campbell SC, Volpert OV, Ivanovich M, Bouck NP. Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998; 58: 1298–1304 Champelovier P, Simon A, Garrel C, Levacher G., Praloran V, Seigneurin D. Is Interferon γ one key of metastatic potential increase in human bladder carcinoma? Clin Cancer Res. 2003; 9: 4562-4569. Chang TT, Chou WN. Antrodia cinnamomea reconsidered and A. salmonea sp. nov. on Cunninghamia konishii in Taiwan. Botanical Bulletin of Academia Sinica 2004; 45: 347–352. Chang, TT, Chou WN. Antrodia cinnamomea sp. nov. on Cinnamomum kanehirai in Taiwan. Mycol Res 1995; 99: 756-758. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-1013. Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, Kumar S. Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 1999; 19: 3479–3484. Chen CH, Yang SW, Shen YC. New steroid acid from Antrodia cinnamonea, a fungal parasite of Cinnamomum micranthum. J Nat Prod 1995; 58:1655-1661. Cherng IH, Chiang HC. Three new triterpenoids from Antrodia cinnamomea. J Nat Prod 1995; 58: 365-371. Cherng IH, Wu DP, Chiang HC. Triterpenoids from Antrodia cinnamomea. Phytochemistry 1996; 41: 263-267. Chiang HC, Wu DP, Cherng IW, Ueng CH. A sesquiterpene lactone, phenyl and biphenyl compounds from Antrodia cinnamomea. Phytochemistry 1995; 39: 613–616. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. J Am Med Assoc 1996; 276: 1957–1963. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998; 81: 730–734. Clemens DL, Calisto LE, Sorrell MF, Tuma DJ. Ethanol metabolism results in G2/M cell-cycle arrest in recombinant HepG2 cells. Hepatology 2003; 38: 385-393 Cohen M. What is complementary medicine? Aust Fam Physician 2000;29: 1125-1128. Conn IG, Vilela MJ, Garrod DR, Crocker J, Wallace DM. Immunohistochemical staining with monoclonal antibody 32-2B to desmosomal glycoprotein 1. Its role in the histological assessment of urothelial carcinomas. Br J Urol 1990; 65:176-80. Cook GP, Hampton JA. Effects of ibuprofen on the in vitro invasiveness of a human transitional cell carcinoma. Anticancer Res 1997; 17: 365-368. Coombs LM, Pigott DA, Sweeney E, Proctor AJ, Eydmann ME, Parkinson C, Knowles MA. Amplification and over-expression of c-erb-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601-608. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, Reuter VE, Pellicer A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347-353. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer [see comments]. J Nat Cancer Inst 1992; 84: 1251-1256. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Reuter VE, Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-1221. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995; 147: 545-560. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-1094. Crew JP, O’Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57: 5281–5285. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265:1582–1584. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA. 1995; 92: 5545-5549. Department of Health, Executive Yuan, Taiwan, R.O.C, Annual Report (2001-2004), Cancer Registration System, Health and National Insurance, Annual Statistics Information Service. http://crs.cph.ntu.edu.tw/crs_c/annual.html. Devlin J, Keen AJ. Knowles MA. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cm of IFNA. Oncogene 1994;9: 2757-2760. Eisenberg DM, Kessler RC, Foster C. Unconvential medicine in the United States. N Engl J Med 1993; 328:246-252. Eisenberg MD, Davis RB, Ettner SL, Appels S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up national survey. JAMA 1998; 280: 1569-1575. Ernst E, White A. The BBC survey of complementary medicine use in the UK. Comp Therap Med 2000; 8:32-36. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 1999; 18: 2789-2797. Fiala ES, Staretz ME, Pandya GA, El-Bayoumy K, Hamilton SR. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis. 1998; 19:597-604. Fisher P, Ward W. Complementary medicine in Europe. BMJ 1994; 309:107-110. Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995; 87: 129-133. Folch J, Lees M, Stanley S G.H. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509. Foty RA, Steinberg MS. Measurement of tumor cell cohesion and suppression of invasion by E- or P-cadherin. Cancer Res 1997; 57: 5033–5036. Fujita J, Nakayama H, Onoue H, Rhim JS, el-Bolkainy MN, el-Aaser AA, Kitamura Y. Frequency of active ras oncogenes in human bladder cancers associated with schistosomiasis. Jpn J Cancer Res 1987; 78: 915-920. Gao Y, Zhou S. The immunomodulating effects of Ganoderma lucidum. Int J Med Mushrooms 2002; 4:1–17. Gee BC, Wilson P, Morris AD, Emerson RM. Herbal is not synonymous with safe. Arch Dermatol 2002; 138:1613. Gee J, Sabichi AL, Grossman HB. Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 2002a; 43: 277-286. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 2004; 315: 624–635. Gilloteaux J, Jamison JM, Venugopal M, Giammar D, Summers JL. Scanning electron microscopy and transmission electron microscopy aspects of synergistic antitumor activity of vitamin C - vitamin K3 combinations against human prostatic carcinoma cells. Scanning Microsc 1995; 9: 159-173. Gilloteaux J, Jamison JM, Von Greunigen D, Arnold D, Summers JL. Autoschizis in ovarian carcinoma cells MDAH as a result of treatment by combined vitamins C and K3. Scanning 2000; 22: 119-120. Gilloteaux J, Arnold D, Taper HS, Summers JL. Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/ menadione on human bladder carcinoma cells. Ultrastructural Pathol 2001; 25: 183-192. Giroldi LA, Bringuier PP, Shimazui T, Jansen K, Schalken JA. Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. Int J Cancer 1999; 82: 70–76. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ. Thrombospondin-1 expression in bladder cancer. association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997; 89 : 219–227. Grossman HB, Liebert M, Antelo D, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998; 4: 829–834. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med 2006; 27:1-93. Habuchi T, Devlin J, Elder PA, Knowles MA. Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci. Oncogene 1995;11: 1671-1674. Hamasaki T, Hattori T, Kimura G., Nakazawa N. Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells. Urol. Res. 1998; 26: 371-376. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70. Hanemaaijer R, Sie CF, Visser H, Scholte L, vanLent N, Toet K, Hoekman K, Verheijen JH. MMP-9 activity in urine from patients with various tumors, as measured by a novel MMP activity assay using modified urokinase as a substrate. Ann NY Acad Sci 1999; 878: 141-149. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-299. Hovey RM, Chu L, Balazs M DeVries S, Moore D, Sauter G, Carroll PR, Waldman FM. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998; 58: 3533-3560. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94:1134-1142. Hseu YC, Chang WC, Hseu YT, Lee CY, Yech YJ, Chen PC, Chen JY, Yang HL. Protection of oxidative damage by aqueous extract from Antrodia camphorata mycelia in normal human erythrocytes. Life Sci. 2002 ; 71: 469–482. Hseu, YC, Yang HL, Lai YC, Lin JG., Chen GW, Chang YH. Induction of apoptosis by Antrodia camphorata in human premyelocytic leukemia HL-60 cells. Nutr Cancer 2004; 48: 189-197. Hsiao G., Shen MY, Lin KH, Lan MH, Wu LY, Chou DS, Lin CH, Su CH, Sheu JR. Antioxidative and hepatoprotective effects of Antrodia camphorata extract. J Agric Food Chem. 2003; 51: 3302-3308. Hsu YL, Kuo YC, Kuo PL, N LT, Kuo YH, Lin CC. Apoptotic effects of extract from Antrodia camphorata fruiting bodies in human hepatocellular carcinoma cell lines. Cancer Lett. 2005; 221: 77-89. Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995; 154: 69–71. Jain K. Swiss embrace complementary medicine. Nat Med 1995; 1:107 Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26. Jamison JM, Gilloteaux J, Nassiri MR, Venugopal M, Neal DR, Summers JL. Cell cycle arrest and autoschizis in a human bladder carcinoma cell line following vitamin C and vitamin K3 treatment. Biochem Pharmacol 2004; 67: 337-351. Jensen PJ, Telegan B, Lavker RM, Wheelock MJ. E-cadherin and P-cadherin have partially redundant roles in human epidermal stratification. Cell Tissue Res 1997; 288: 307-16. Jiang C, Ganther H, Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinogen 2000; 29: 236–250. Kallioniemi A, Kallioniemi OP, Citro G, Sauter G, DeVries S, Kerschmann R, Caroll P, Waldman F. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995; 12: 213-219. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest 2001; 48: 31–43. Kawasaki T, Tomita Y, Watanabe R, Tanikawa T, Kumanishi T, Sato S. mRNA and protein expression of p53 mutations in human bladder cancer cell lines. Cancer Lett. 1994; 82: 113-121. Kawasaki T, Tomita Y, Bilim V, Takeda M, Takahashi K, Kumanishi T. Abrogation of apoptosis induced b DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and /or p53 gene alterations. Int J Cancer 1996; 68: 501-505. Keen AJ, Knowles MA. Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. Oncogene 1994; 9: 2083-2088. Kiremidjian-Schumacher L, Roy M, Glickman R, Schneider K, Rothstein S, Cooper J, Hochster H, Kim M, Newman R. Selenium and immunocompetence in patients with head and neck cancer. 2000; 73: 97-111. Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designated restriction fragment length polymorohisms, and direct sequencing. Cancer Res 1993; 53: 133-139. Knowles MA. The genetics of transitional cell carcinoma: progress and potential clinical application. BJU Int 1999; 84: 412-427. Kotake T, Saiki S, Kinouchi T, Shiku H, Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res 1990; 81: 1198-1201. Kubota Y, Miyamato H, Noguchi S, Shuin T, Kitamura H, Xu HJ, Hu SX, Benedict WF. The loss of retinoblastoma gene in association with c-myc and transforming growth factor-beta 1 gene expression in human bladder cancer. J Urol. 1995; 154(2 Pt 1):371-4. Kumar NB, Allen K, Bell H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control 2005; 12:149-157. Lee IH, Huang RL, Chen CT, Chen HC, Chen HC, Hsu WC, Lu MK. Antrodia camphorata polysaccharides exhibit anti-hepatitis B virus effects. FEMS Microbiol Lett. 2002; 209: 63–67. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of Bladder Cancer: A Review. Eur Urol 2006; 49: 226–234. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331. Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995; 175: 203-210. Liu J, Zhang X, Yang F, Li T, Wei D, Ren Y. Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion. Cancer Chem Pharm 2005; Aug 2, 1-7 [Epub ahead of print]. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Nat Cancer Inst 1992; 84: 1256-1261. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, Montironi R. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004; 122: 444-452. Lu J, Jiang C. Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects. Nutr Cancer 2001; 40: 64–73. Malone PR, Visvanathan KV, Ponder BA, Shearer RJ, Summerhayes IC. Oncogenes and bladder cancer. Br J Urol 1985; 57:664-7. Matanoski GM, Elliott EA. Bladder cancer epidemiology. Epidemiol. Rev. 1981; 3: 203-229. McGarvey TW, Tait E, Tamaszewski JE, Malkowicz SB. Expression of transforming growth factor-beta receptors and related cell-cycle components in transitional-cell carcinoma of the bladder. Mol Urol 1999; 3: 371–380. Memon AA, Chang JW, Oh BR, Yoo YJ. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev 2005; 29: 249-255. Menges LJ. Beyond the Anglophone world: regular and alternative medicine: the state of affairs in the Neitherlands. Soc Sci Med 1994; 39:871-873. Mialhe A, Louis J, Montlevier S, Peoch M, Pasquier D, Bosson JL, Rambeaud JJ, Seigneurin D. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis 1997; 17: 124–137. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999; 147: 631–644. Nutt JE, Mellon JK, Qureshi K, Lunec J. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br J Cancer 1998; 78: 215–220. Olumi AF, Skinner EC, Tsai YC, Jones PA. Molecular analysis of human bladder cancer. Semi. Urol. 1990; 4: 270-277. Ooi VE, Liu F. Immunomodulation and anticancer activity of polysaccharide–protein complexes. Curr Med Chem 2000; 7: 715–729. Orlow I, La Rue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 1999; 155: 105–113. Oya M, Schmidt B, Schmitz-Dräger BJ, Schulz WA. Expression of G1?_ S transition regulatory molecules in human urothelial cancer. Jpn J Cancer Res 1998; 89: 719-726. Palmero I, Pantoja C, Serrano M. p19ARF links the tumor suppressor p53 to Ras. Nature 1998; 395:125-126. Papathoma AS, Petraki C, Grigorakis A, Papakonstantinou H, Karavana V, Stefanakis S, Sotsiou F, Pintzas A. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000; 20: 2009–2013. Pasanen AL, Yli-Pietila K, Pasanen P, Kalliokoski P, Tarhanen J. Ergosterol content in various fungal species and biocontaminated building materials. Appl Environ Microb 1999; 65: 138-142. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 1998; 92: 713-723. Proctor AJ, Coombs LM, Cairns JP, Knowles MA. Amplification at chromosome 11q13 in transitional cell tumours of the bladder. Oncogene 1991; 6:789-795. Raich PC, Lu J, Thompson HJ, Combs GF Jr. Selenium in cancer prevention: clinical issues and implications. Cancer Invest 2001; 19: 540–553. Rees R. Complementary medicine in Nordic countries. Altern Therap Health Med 1997; 3: 92-93. Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol Carcinog 2002; 34: 187–198. Richter J, Beffa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998; 153: 1615-1621. Richter J, Jiang F, Gorog JP, Sartorius G, Egenter C, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997; 57: 2860-2864. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumor of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 1970; 24: 746-754. Safir N, Wendel A, Saile R, Chabraoui L. The effect of selenium on immune functions of J774.1 cells. Clin Chem Lab Med 2003; 41:1005–1011. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto T, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992; 70: 2493-2498. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F. Heterogenity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993; 53: 2199-2203. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593-602. Shapiro L, Fannon AM, Kwong PD Thompson A, Lehmann MS, Grubel G, Legrand JF, Als-Nielsen J, Colman DR, Hendrickson WA. Structural basis of cell-cell adhesion by cadherins. Nature 1995; 374: 327–337. Shen, YC, Chou CJ, Wang YH, Chen CF, Chou YC, Lu MK. Anti-inflammatory activity of the extracts from mycelia of Antrodia camphorata cultured with water-soluble fractions from five different Cinamomum species. FEMS Microbiol. Lett. 2004a; 231: 137-143. Shen, YC, Wang YH, Chou YC, Chen CF, Lin, LC, Chang TT, Tien JH, Chou CJ. Evaluation of the anti-inflammatory activity of zhankuic acids isolated from the fruiting bodies of Antrodia camphorata. Plant. Med 2004b; 70: 310-314. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997; 75:1788-1792. Sidransky D, Von Eschenbach A, Tsai YC YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706-9. Simoneau AR, Spruck CH3rd, Gonzalez-Zulueta M, Gonzalgo ML, Chan MF, Tsai YC, Dean M, Steven K, Horn T, Jones PA. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS 1 and PTC mutations. Cancer Res 1996; 56: 5039-5043. Sinha R, El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 2004; 4:13–28. Skinner DG., Lieskovsky G.. 16 years experience in the management of patients with deeply invasive bladder cancer. Eur Urol 1988; 14:30-31. Song TY, Hsu SL, Yen GC. Induction of apoptosis in human hepatoma cells by mycelia of Antrodia camphorate in submerged culture. J Ethnopharmacol. 2005;100 (1-2):158-67. Song, TY, Yen GC. Protective effects of fermented filtrate from Antrodia camphorata in submerged culture against CCl4-induced hepatic toxicity in rats. J Agric Food Chem 2003; 51: 1571–1577. Sparkes RS, Sparkes MC, Wilson MG, Towner JW, Benedict W, Murphree AL, Yunis JJ. Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13q14. Science 1980; 208: 1042-1044. Subbiah MT, Abplanalp W. Ergosterol (major sterol of baker''s and brewer''s yeast extracts) inhibits the growth of human breast cancer cells in vitro and the potential role of its oxidation products. Int J Vitam Nutr Res 2003; 73:19-23. Su, C.H., 2002. Health Guardian Angel: Antrodia camphorata, 1st ed. EKS Book Publishing Co., Taipei. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451–1455. Tanagho EA and McAninch JW (eds): Smith’s General Urology, 15th edition, pp364, 2000, McGraw-hill Publisher, Columbus, USA. The US National Centre for Complementary and Alternative Medicine. Available from URL: http://nccam.nih.gov/health/whatiscam/index.htmm Tselepis C, Chidgey M, North A, Garrod D. Desmosomal adhesion inhibits invasive behaviour. Proc Natl Acad Sci USA 1998; 95: 8064–8069. Tzianabos AO. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 2000; 13: 523–533. Underwood M, Bartlett J, Reeves J, Gardiner S, Scott R, Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-2430. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Cancer Biol 1999; 9: 211–205. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer. Prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157–166. Wang GJ, Tseng HW, Chou CJ, Tsai TH, Chen CT, Lu MK. The vasorelaxation of Antrodia camphorata mycelia: involvement of endothelial Ca(2+)-NO-cGMP pathway. Life Sci. 2003, 73, 2769–2783. Wasser SP, Weis AL. Medicinal properties of substances occurring in higher basidiomycetes mushrooms: current perspectives (review). Int J Med Mushrooms 1999; 1:31–62. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002; 60:258–274. WHO (2004) WHO Classification Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France. WHO Traditional Medicine Strategy 2002-2005, World Health Organization, Geneva, 2000. William SG, Stein JP. Molecular pathways in bladder cancer. Urol Res 2004; 32: 373-385. Williamson MP, Elder PA, Knowles MA. The spectrum of TP53 mutations in bladder carcinoma. Genes, Chromosomes Cancer 1994; 9: 108-118. Wu SH, Ryvarden L, Chang TT. Antrodia camphorata ("niu-chang-chih"), new combination of a medicinal fungus in Taiwan. Bot. Bull. Acad. Sin.1997, 38, 273–275. Wu, SH, Yu ZH, Dai YC, Chen CT, Su CH, Chen LC, Hsu WC, and Hwang GY. Taiwanofungus, a polypore new genus. Fung. Sci. 2004, 19(3-4); 109-116. Wynder EL, Goldsmith K. The epidemiology of bladder cancer: a second look. Cancer 1977; 40: 1246-1268. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 1999; 62: 2281–2290. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704. Xu HJ, Cairns P, Hu SX Knowles MA, Benedict WF. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781-784. Yang SW, Shen YC, Chen CH. Steroids and triterpenoids of Antodia cinnamomea—A fungus parasitic on Cinnamomum micranthum. Phytochemistry 1996; 41: 1389–1392. Yazawa Y, Yokota M, Sugiyama K. Antitumor promoting effect of an active component of Polyporus, ergosterol and related compounds on rat urinary bladder carcinogenesis in a short-term test with concanavalin A. Biol Pharm Bull 2000; 23: 1298-1302. Yeh, MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP, Han SH. Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). J Surg Oncol 1988; 37: 177-184. Zaidman BZ, Yassin M, Mahajna J, Wasser SP. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 2005; 67: 453-468. Zeng ZS, Guillem JG.. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer 1998; 78: 349-353. Zhang J, Shen Y, Liu J, Wei D. Antimetastatic effect of prodigiosin through inhibition of tumor invasion. Biochem Pharmol 2005; 69: 407-414. Zhang M, and Su Q. Ganoderma comphoratum, a new taxon in genus Ganoderma from Taiwan, China. Acta Bot. Yunnanica 1990;12: 395-396. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilize p53: aRF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathway. Cell 1998; 92: 725-734.
|